Angiotensin-(1-7) augments endothelium-dependent relaxations of porcine coronary arteries to bradykinin by inhibiting angiotensin-converting enzyme 1

Journal of Cardiovascular Pharmacology

Volumn 63, Issue 5, 2014, Pages 453-460

  Raffai, Gábor ^a   Khang, Gilson ^a   Vanhoutte, Paul M ^a,b  

^a Chonbuk National University   (South Korea)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Angiotensin (1 7); Angiotensin converting enzyme 2; Bradykinin; Captopril; Diminazene aceturate; Hyperpolarization; Nitric oxide; Renin angiotensin system

Indexed keywords

1 [(2 CHLOROPHENYL)DIPHENYLMETHYL] 1H PYRAZOLE; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 6,10 DIAZA 3(1,3)8,(1,4) DIBENZENA 1,5(1,4) DIQUINOLINACYCLODECAPHANE; ANGIOTENSIN[1-7]; ARGININE METHYL ESTER; BRADYKININ; CAPTOPRIL; DIMINAZENE ACETURATE; DIPEPTIDYL CARBOXYPEPTIDASE; INDOMETACIN; ANGIOTENSIN I; ANGIOTENSIN I (1-7); DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRIC OXIDE; PEPTIDE FRAGMENT; VASODILATOR AGENT;

ANIMAL TISSUE; ARTICLE; BLOOD VESSEL TONE; CONTROLLED STUDY; CORONARY ARTERY; HYPERPOLARIZATION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SWINE; VASCULAR ENDOTHELIUM; VASODILATATION; ANIMAL; CORONARY BLOOD VESSEL; DRUG EFFECTS; ENDOTHELIUM; HEART; MUSCLE ISOMETRIC CONTRACTION; MUSCLE RELAXATION; MUSCLE TONE; PHYSIOLOGY;

ANGIOTENSIN I; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BRADYKININ; CORONARY VESSELS; ENDOTHELIUM; HEART; IN VITRO TECHNIQUES; ISOMETRIC CONTRACTION; MUSCLE RELAXATION; MUSCLE TONUS; NITRIC OXIDE; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; SWINE; VASODILATOR AGENTS;

EID: 84900863200     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000069     Document Type: Article

References (64)

1. Sampaio WO, Nascimento AA, Santos RA. Systemic and regional hemodynamic effects of angiotensin-(1-7) in rats. Am J Physiol Heart Circ Physiol. 2003;284:H1985-H1994.
2. Benter IF, Diz DI, Ferrario CM. Cardiovascular actions of angiotensin (1-7). Peptides. 1993;14:679-684.
3. Oliveira MA, Fortes ZB, Santos RA, et al. Synergistic effect of angiotensin-( 1-7) on bradykinin arteriolar dilation in vivo. Peptides. 1999;20: 1195-1201.
4. Fernandes L, Fortes ZB, Nigro D, et al. Potentiation of bradykinin by angiotensin-(1-7) on arterioles of spontaneously hypertensive rats studied in vivo. Hypertension. 2001;37(2 part 2):703-709.
5. Durand MJ, Raffai G, Weinberg BD, et al. Angiotensin-(1-7) and lowdose angiotensin II infusion reverse salt-induced endothelial dysfunction via different mechanisms in rat middle cerebral arteries. Am J Physiol Heart Circ Physiol. 2010;299:H1024-H1033.
6. Brosnihan KB, Li P, Ferrario CM. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension. 1996;27(3 pt 2):523-528.
7. Brosnihan KB, Li P, Tallant EA, et al. Angiotensin-(1-7): a novel vasodilator of the coronary circulation. Biol Res. 1998;31:227-234.
8. Ferreira AJ, Santos RA. Cardiovascular actions of angiotensin-(1-7). Braz J Med Biol Res. 2005;38:499-507.
9. Trask AJ, Ferrario CM. Angiotensin-(1-7): pharmacology and new perspectives in cardiovascular treatments. Cardiovasc Drug Rev. 2007;25: 162-174.
10. Tipnis SR, Hooper NM, Hyde R, et al. A human homolog of angiotensinconverting enzyme. Cloning and functional expression as a captoprilinsensitive carboxypeptidase. J Biol Chem. 2000;275:33238-33243.
11. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87:E1-E9.
12. Kulemina LV, Ostrov DA. Prediction of off-target effects on angiotensinconverting enzyme 2. J Biomol Screen. 2011;16:878-885.
13. Santos RA, Ferreira AJ. Angiotensin-(1-7) and the renin-angiotensin system. Curr Opin Nephrol Hypertens. 2007;16:122-128.
14. Ferrario CM, Ahmad S, Joyner J, et al. Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7). Adv Pharmacol. 2010;59:197-233.
15. Ferrario CM, Trask AJ, Jessup JA. Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol. 2005;289:H2281-H2290.
16. Iusuf D, Henning RH, van Gilst WH, et al. Angiotensin-(1-7): pharmacological properties and pharmacotherapeutic perspectives. Eur J Pharmacol. 2008;585:303-312.
17. Santos RA, Ferreira AJ. Pharmacological effects of AVE 0991, a nonpeptide angiotensin-(1-7) receptor agonist. Cardiovasc Drug Rev. 2006; 24:239-246.
18. Souza dos Santos RA, Passaglio KT, Pesquero JB, et al. Interactions between angiotensin-(1-7), kinins, and angiotensin II in kidney and blood vessels. Hypertension. 2001;38(3 pt 2):660-664.
19. Raizada MK, Ferreira AJ. ACE2: a new target for cardiovascular disease therapeutics. J Cardiovasc Pharmacol. 2007;50:112-119.
20. Santos RA, Simoes e Silva AC, Maric C, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A. 2003;100:8258-8263.
21. Sampaio WO, Souza dos Santos RA, Faria-Silva R, et al. Angiotensin-(1- 7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension. 2007;49:185-192.
22. Wiemer G, Dobrucki LW, Louka FR, et al. AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium. Hypertension. 2002;40:847-852.
23. Heitsch H, Brovkovych S, Malinski T, et al. Angiotensin-(1-7)-Stimulated nitric oxide and Superoxide release from endothelial Cells. Hypertension. 2001;37:72-76.
24. Pinheiro SV, Simoes e Silva AC, Sampaio WO, et al. Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension. 2004;44:490-496.
25. Santos RA, Campagnole-Santos MJ, Baracho NC, et al. Characterization of a new angiotensin antagonist selective for angiotensin-(1-7): evidence that the actions of angiotensin-(1-7) are mediated by specific angiotensin receptors. Brain Res Bull. 1994;35:293-298.
26. Faria-Silva R, Duarte FV, Santos RA. Short-term angiotensin(1-7) receptor MAS stimulation improves endothelial function in normotensive rats. Hypertension. 2005;46:948-952.
27. Gorelik G, Carbini LA, Scicli AG. Angiotensin 1-7 induces bradykininmediated relaxation in porcine coronary artery. J Pharmacol Exp Ther. 1998;286:403-410.
28. Santos RA, Ferreira AJ, Simoes e Silva AC. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp Physiol. 2008;93:519-527.
29. Paula RD, Lima CV, Khosla MC, et al. Angiotensin-(1-7) potentiates the hypotensive effect of bradykinin in conscious rats. Hypertension. 1995; 26(6 pt 2):1154-1159.
30. Paula RD, Lima CV, Britto RR, et al. Potentiation of the hypotensive effect of bradykinin by angiotensin-(1-7)-related peptides. Peptides. 1999;20:493-500.
31. Ueda S, Masumori-Maemoto S, Wada A, et al. Angiotensin(1-7) potentiates bradykinin-induced vasodilatation in man. J Hypertens. 2001;19:2001-2009.
32. Li P, Chappell MC, Ferrario CM, et al. Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension. 1997;29(1 pt 2):394-400.
33. Tom B, de VR, Saxena PR, et al. Bradykinin potentiation by angiotensin- (1-7) and ACE inhibitors correlates with ACE C- and N-domail blockade. Hypertension. 2001;38:95-99.
34. Roks AJ, van Geel PP, Pinto YM, et al. Angiotensin-(1-7) is a modulator of the human renin-angiotensin system. Hypertension. 1999;34:296-301.
35. Maia LG, Ramos MC, Fernandes L, et al, Souza dos Santos RA. Angiotensin- (1-7) antagonist A-779 attenuates the potentiation of bradykinin by captopril in rats. J Cardiovasc Pharmacol. 2004;43:685-691.
36. Fleming I, Kohlstedt K, Busse R. The tissue renin-angiotensin system and intracellular signalling. Curr Opin Nephrol Hypertens. 2006;15:8-13.
37. Nguyen Dinh CA, Touyz RM. A new look at the renin-angiotensin system-focusing on the vascular system. Peptides. 2011;32:2141-2150.
38. Mecca AP, Regenhardt RW, O'Connor TE, et al. Cerebroprotection by angiotensin-(1-7) in endothelin-1-induced ischaemic stroke. Exp Physiol. 2011;96:1084-1096.
39. Qi Y, Zhang J, Cole-Jeffrey CT, et al. Diminazene aceturate enhances Angiotensin-converting enzyme 2 activity and attenuates ischemiainduced cardiac pathophysiology. Hypertension. 2013;62:746-752.
40. Shenoy V, Gjymishka A, Jarajapu YP, et al. Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models. Am J Respir Crit Care Med. 2013;187:648-657.
41. Olmos L, Mombouli JV, Illiano S, et al. cGMP mediates the desensitization to bradykinin in isolated canine coronary arteries. Am J Phys. 1995;268(2 pt 2):H865-H870.
42. Ferrario CM. ACE2: more of Ang-(1-7) or less Ang II? Curr Opin Nephrol Hypertens. 2011;20:1-6.
43. Auch-Schwelk W, Kuchenbuch C, Claus M, et al. Local regulation of vascular tone by bradykinin and angiotensin converting enzyme inhibitors. Eur Heart J. 1993;14(suppl I):154-160.
44. Zanzinger J, Zheng X, Bassenge E. Endothelium dependent vasomotor responses to endogenous agonists are potentiated following ACE inhibition by a bradykinin dependent mechanism. Cardiovasc Res. 1994;28: 209-214.
45. Mombouli JV, Vanhoutte PM. Kinins and endothelium-dependent relaxations to converting enzyme inhibitors in perfused canine arteries. J Cardiovasc Pharmacol. 1991;18:926-927.
46. Mombouli JV, Illiano S, Nagao T, et al. Potentiation of endotheliumdependent relaxations to bradykinin by angiotensin I converting enzyme inhibitors in canine coronary artery involves both endothelium-derived relaxing and hyperpolarizing factors. Circ Res. 1992;71:137-144.
47. Tom B, Dendorfer A, de VR, et al. Bradykinin potentiation by ACE inhibitors: a matter of metabolism. Br J Pharmacol. 2002;137:276-284.
48. Richer C, Giroux B, Plouin PF, et al. Captopril: pharmacokinetics, antihypertensive and biological effects in hypertensive patients. Br J Clin Pharmacol. 1984;17:243-250.
49. Kocks MJ, Lely AT, Boomsma F, et al. Sodium status and angiotensinconverting enzyme inhibition: effects on plasma angiotensin-(1-7) in healthy man. J Hypertens. 2005;23:597-602.
50. Bader M. Tissue renin-angiotensin-aldosterone systems: Targets for pharmacological therapy. Annu Rev Pharmacol Toxicol. 2010;50:439-465.
51. Paul M, Poyan MA, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev. 2006;86:747-803.
52. Erdos EG, Tan F, Skidgel RA. Angiotensin I-converting enzyme inhibitors are allosteric enhancers of kinin B1 and B2 receptor function. Hypertension. 2010;55:214-220.
53. Gauthier KM, Cepura CJ, Campbell WB. ACE inhibition enhances bradykinin relaxations through nitric oxide and B1 receptor activation in bovine coronary arteries. Biol Chem. 2013;394:1205-1212.
54. Gougat J, Ferrari B, Sarran L, et al. SSR240612 [(2R)-2-[(3R)-3-(1,3- benzodioxol-5-yl)-3-[[(6-methoxy-2-naphthyl)sulfonyl]amino] propanoyl) amino]-3-(4-[[2R,6S)-2,6-dimethylpiperidinyl]methyl]phenyl)-N-isopropyl -N-methylpropanamide hydrochloride], a new nonpeptide antagonist of the bradykinin B1 receptor: biochemical and pharmacological characterization. J Pharmacol Exp Ther. 2004;309:661-669.
55. Nagao T, Vanhoutte PM. Hyperpolarization as a mechanism for endothelium-dependent relaxations in the porcine coronary artery. J Physiol. 1992;445:355-367.
56. Weston AH, Feletou M, Vanhoutte PM, et al. Bradykinin-induced, endothelium-dependent responses in porcine coronary arteries: involvement of potassium channel activation and epoxyeicosatrienoic acids. Br J Pharmacol. 2005;145:775-784.
57. Hernanz R, Alonso MJ, Baena AB, et al. Mechanisms of bradykinininduced relaxation in pig coronary arteries. Methods Find Exp Clin Pharmacol. 1999;21:243-251.
58. Rees DD, Palmer RM, Schulz R, et al. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol. 1990;101:746-752.
59. Shen TY, Winter CA. Chemical and biological studies on indomethacin, sulindac and their analogs. Adv Drug Res. 1977;12:90-245.
60. Campos RJ, Galanakis D, Piergentili A, et al. Synthesis, molecular modeling, and pharmacological testing of bis-quinolinium cyclophanes: potent, non-peptidic blockers of the apamin-sensitive Ca(2+)-activated K(+) channel. J Med Chem. 2000;43:420-431.
61. Wulff H, Miller MJ, Hansel W, et al. Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: a potential immunosuppressant. Proc Natl Acad Sci U S A. 2000;97:8151-8156.
62. Almeida AP, Frabregas BC, Madureira MM, et al. Angiotensin-(1-7) potentiates the coronary vasodilatatory effect of bradykinin in the isolated rat heart. Braz J Med Biol Res. 2000;33:709-713.
63. Nakashima M, Mombouli JV, Taylor AA, et al. Endothelium-dependent hyperpolarization caused by bradykinin in human coronary arteries. J Clin Invest. 1993;92:2867-2871.
64. Garthwaite J, Southam E, Boulton CL, et al. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo [4,3-a]quinoxalin-1-one. Mol Pharmacol. 1995;48:184-188.